Group 1 (n=61) Group 2 (n=104) P
Age (years), median (range) 39 (24 – 81) 40 (23 – 81) 0.94
BMI (kg/m2), median (range) 23.1 (19.3 – 31.6) 24.2 (18.0 – 41.0) 0.27
History of abdominal surgery 19 (31,1) 33 (31,7) 1.00
ASA scorea 60 104 0.22
1
44 (73.3)
86 (82.7)
≥2
16 (26.7)
18 (17.3)
FIGO stage 1.00b
IA1 and IA2
4 (6.6)
7 (6.7)
IB1 and IIA
57(93.4)
97 (93.3)
Histology 0.58
Squamous cell
41 (67.2)
71 (68.3)
Adenocarcinoma
17 (27.9)
24 (23.1)
Other (adenosquamous, clearcell, villoglandular)
3 (4.9)
9 (8.7)
Grade c 60 102 0.26
I
10 (16.7)
27 (26.5)
II
36 (60.0)
49 (48.0)
III
14 (23.3)
26 (25.5)
Type of procedure 0.38
PLND and RH
43 (70.5)
59 (56.7)
PLND and RVT
8 (13.1)
20 (19.2)
PLND only
4 (6.6)
9 (8.7)
Otherd
6 (9.8)
16 (15.4)
SN procedure performed 53 (86.9) 92 (88.5) 0.96
LN harvested (excluding SN only), median (range) 27 (12-56) 24 (10-61) 0.31
LN harvested (excluding SN only)
<17 lymph nodes harvestede
2 (3.3)
11 (11.0)
0.13b
≥17 lymph nodes harvested
58 (96.7)
89 (89.0)
Positive LN status 7 (11.5) 14 (13.5) 0.90
Positive LVSI 28 (45.9) 47 (46.1) 1.00
Positive parametrial involvement 4 (6.6) 4 (3.8) 0.47b
Adjuvant or adjusted treatment 15 (24.6) 20 (19.2) 0.54
Radiotherapy
10 (16.4)
8 (7.7)
0.22
Chemoradiation
5 (8.2)
12 (11.5)
Follow up duration (months), median (range) 62 (14-132) 43 (3-91) <0.001f